Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin plus mFOLFOX for second-line malignant biliary tract tumors
ChiCTR2500100484Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Icaritin, oxaliplatin, fluorouracil and folinic acid in biliary cancer and cholangiocarcinoma (CCA), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Icaritinoxaliplatinfluorouracilfolinic acid
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2500100484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100484.